Raed M. Maklad

Mr. Raed M. Maklad

School of Chemistry, The University of Sydney, Sydney, New South Wales, Australia
orcid
I am a chemist who dreams of working out the connection betw...

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
TITamer Ibrahim
Tamer Ibrahim
GAGhada Abada
Ghada Abada
MDMarcel Dammann
Marcel Dammann
Raed M. MakladRaed M. Maklad
Raed M. Maklad
WEWagdy M. Eldehna
Wagdy M. Eldehna
FBFrank M. Beockler
Frank M. Beockler

27 October 2022 in RSC Advances
Verified
Journal Article
Open access
PDF file
TATarfah Al-Warhi
Tarfah Al-Warhi
DEDiaaeldin M. Elimam
Diaaeldin M. Elimam
ZEZainab M. Elsayed
Zainab M. Elsayed
MAMarwa Abdel-Aziz
Marwa Abdel-Aziz
Raed M. MakladRaed M. Maklad
Raed M. Maklad
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
Microbial Multidrug Resistance (MDR) is an emerging global crisis. Derivatization of natural or synthetic scaffolds is among the most reliable strategies to search for and obtain novel antimicrobial agents for the treatment of MDR infections. Here, we successfully manipulated the synthetically flexible isatin moieties to synthesize 22 thiazolyl-pyrazolines hybrids, and assessed their potential antimicrobial activities in vitro against various MDR pathogens, using the broth microdilution calorimetric XTT reduction method. We chose 5 strains to represent the major MDR microorganisms, viz: Methicillin-resistant S. aureus (MRSA), and Vancomycin-resistant E. faecalis (VRE) as Gram-positive bacteria; Carbapenem-resistant K. pneumonia (CRKP), and Extended-spectrum beta-lactamase E. coli (ESBL-E), as Gram-negative bacteria; and Fluconazole-resistant C. albicans (FRCA), as a yeast-like unicellular fungus. The cytotoxicity of compounds 9f and 10h towards mammalian lung fibroblast (MRC-5) cells demonstrated their potential satisfactory safety margin as represented by their relatively high IC50 values. The target compounds showed promising anti-MDR activities, suggesting they are potential leads for further development and in vivo studies.

26 April 2022 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
Raed M. MakladRaed M. Maklad
Raed M. Maklad
HAHadia Almahli
Hadia Almahli
TATarfah Al-Warhi
Tarfah Al-Warhi
EEEslam B. Elkaeed
Eslam B. Elkaeed
AKAhmed M. El Kerdawy
Ahmed M. El Kerdawy
In the current work, a hybridisation strategy was adopted between the privileged building blocks, benzofuran and piperazine, with the aim of designing novel CDK2 type II inhibitors. The hybrid structures were linked to different aromatic semicarbazide, thiosemicarbazide, or acylhydrazone tails to anchor the designed inhibitors onto the CDK2 kinase domain. The designed compounds showed promising CDK2 inhibitory activity. Compounds 9h, 11d, 11e and 13c showed potent inhibitory activity (IC50 of 40.91, 41.70, 46.88, and 52.63 nM, respectively) compared to staurosporine (IC50 of 56.76 nM). Moreover, benzofurans 9e, 9h, 11d, and 13b showed promising antiproliferative activities towards different cancer cell lines, and non-significant cytotoxicity on normal lung fibroblasts MRC-5 cell line. Furthermore, a cell cycle analysis as well as Annexin V-FITC apoptosis assay on Panc-1 cell line were performed. Molecular docking simulations were performed to explore the ability of target benzofurans to adopt the common binding pattern of CDK2 type II inhibitors.

1 January 2021 in Journal of Enzyme Inhibition and Medicinal Chemistry
Verified
Journal Article
Open access
MAMohammad Alsanea
Mohammad Alsanea
GAGhada Al-Ansary
Ghada Al-Ansary
ZEZainab M. Elsayed
Zainab M. Elsayed
Raed M. MakladRaed M. Maklad
Raed M. Maklad
EEEslam B. Elkaeed
Eslam B. Elkaeed
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
As one of the most lethal malignancies, lung cancer is considered to account for approximately one-fifth of all malignant tumours-related deaths worldwide. This study reports the synthesis and in vitro biological assessment of two sets of 3-methylbenzofurans (4a–d, 6a–c, 8a–c and 11) and 3-(morpholinomethyl)benzofurans (15a–c, 16a–b, 17a–b and 18) as potential anticancer agents towards non-small cell lung carcinoma A549 and NCI-H23 cell lines, with VEGFR-2 inhibitory activity. The target benzofuran-based derivatives efficiently inhibited the growth of both A549 and NCI-H23 cell lines with IC50 spanning in ranges 1.48–47.02 and 0.49–68.9 µM, respectively. The three most active benzofurans (4b, 15a and 16a) were further investigated for their effects on the cell cycle progression and apoptosis in A549 (for 4b) and NCI-H23 (for 15a and 16a) cell lines. Furthermore, benzofurans 4b, 15a and 16a displayed good VEGFR-2 inhibitory activity with IC50 equal 77.97, 132.5 and 45.4 nM, respectively.

4 April 2023 in Molecules
Verified
Journal Article
Open access
PDF file
TATarfah Al-Warhi
Tarfah Al-Warhi
Hadia AlmahliHadia Almahli
Hadia Almahli
Raed M. MakladRaed M. Maklad
Raed M. Maklad
ZEZainab M. Elsayed
Zainab M. Elsayed
MHMahmoud El Hassab
Mahmoud El Hassab
MEMohamed Kandeel El-Ashrey
Mohamed Kandeel El-Ashrey
Human health is experiencing several obstacles in the modern medical era, particularly cancer. As a result, the cancer therapeutic arsenal should be continually expanded with innovative small molecules that preferentially target tumour cells. In this study, we describe the development of two small molecule series (7a–d and 12a–e) based on the 1-benzyl-5-bromoindolin-2-one scaffold that connected through a hydrazone linker to a 4-arylthiazole (7a–d) or 4-methyl-5-(aryldiazenyl)thiazole (12a–e) moiety. The anticancer activity of all the reported indolin-2-one derivatives was assessed against breast (MCF-7) and lung (A-549) cancer cell lines. The 4-arylthiazole-bearing derivatives 7c and 7d revealed the best anticancer activity toward MCF-7 cells (IC50 = 7.17 ± 0.94 and 2.93 ± 0.47, respectively). Furthermore, the VEGFR-2 inhibitory activity for 7c and 7d was evaluated. Both molecules disclosed good inhibitory activity, and their IC50 values were equal to 0.728 µM and 0.503 µM, respectively. Additionally, the impacts of 7d on the cell cycle phases as well as on the levels of different apoptotic markers (caspase-3, caspase-9, Bax, and Bcl-2) were assessed. Molecular docking and dynamic simulations are carried out to explore the binding mode of 7d within the VEGFR-2 active site.

18 September 2024 in Bioorganic Chemistry
Verified
Journal Article
Closed access
Wagdy Mohamed EldehnaWagdy Mohamed Eldehna
Wagdy Mohamed Eldehna
YHYoumna A. Habib
Youmna A. Habib
AMAbeer E. Mahmoud
Abeer E. Mahmoud
MBMohamed F. Barghash
Mohamed F. Barghash
ZEZainab M. Elsayed
Zainab M. Elsayed
AKAhmed M. El Kerdawy
Ahmed M. El Kerdawy